The ACR and Rheumatology Research Foundation hope a new report on rheumatic disease research can leverage more money for ACR members, funding future research…

Subcategories:EthicsLegal UpdatesLegislation & AdvocacyResearch Rheum
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!

The ACR and Rheumatology Research Foundation hope a new report on rheumatic disease research can leverage more money for ACR members, funding future research…

Rheumatologists in community-based practices work closely with patients, which allows them to notice trends and nuances researchers may not. Unfortunately, few opportunities exist for rheumatologists to test their observations through research, in addition to taking care of patients. Limited funding, time constraints and competition from larger academic medical centers are some of the barriers that…

As president of the Georgia Society of Rheumatology (GSR), Wambui Machua, MD, a rheumatologist with Piedmont Physicians Rheumatology, Atlanta, oversees a membership of 90 rheumatologists, six orthopedists, two nurses, 85 physician assistants and 27 fellows and residents. According to Dr. Machua, the GSR, founded in 1967, continues to pursue its original mission of providing educational…

Renée Bacher |
Rheumatologists should not be falsely reassured by a normal mean blood pressure in lupus patients, according to a study from Johns Hopkins University that found age-related blood pressure patterns in systemic lupus erythematosus (SLE) differ from the general population and that increased diastolic blood pressure variability (BPV) is highly associated with cardiovascular events in SLE.1…

Bryn Nelson, PhD |
As useful stand-ins for biologics targeting a range of inflammatory diseases, biosimilars have made significant inroads across Europe as less expensive alternatives. Denmark, for example, realized a cost savings of 64% after instituting a mandatory national switch from the originator infliximab to its biosimilar counterpart. In the U.S., however, a considerably smaller fraction of rheumatologists…

Ellen M. Gravallese, MD |
These are truly extraordinary times. The COVID-19 pandemic has affected the rheumatology community, both providers and patients, in many ways, and our advocacy efforts are now more important than ever to ensure policymakers hear us and help address the issues facing our community. As with so many things during this pandemic, we are reimagining advocacy…

David Y. Chen, MD, PhD, & Eric J. Gapud, MD, PhD, on behalf of the ACR Committee for Ethics & Conflicts of Interest |
Prescribing stewardship is just one ethical consideration facing rheumatologists during the COVID-19 pandemic.
Blair Solow, MD |
Although the COVID-19 outbreak has shifted the focus and approach of advocacy efforts, ACR staff and the Government Affairs Committee continue to work on behalf of rheumatology providers and patients.
Despite efforts by the ACR and other organizations, Blue Cross Blue Shield of Tennessee has indicated that it will move forward with implementation of its specialty pharmacy acquisition mandate on July 1, 2020.
Michael Erman |
NEW YORK, June 4 (Reuters)—Three of the authors of an influential article that found hydroxychloroquine (HCQ) increased the risk of death in COVID-19 patients retracted the study, citing concerns about the quality of the data behind it. The anti-malarial drug has been controversial in part due to support from U.S. President Donald Trump, as well…